Want to see SE:IBT.B full AI Analyst Report?
Infant Bacterial Therapeutics AB (IBT.B) Financial Statements
Infant Bacterial Therapeutics AB Financial Overview
Infant Bacterial Therapeutics AB's market cap is currently $885.07M. The company's EPS TTM is $-6.09; its P/E ratio is -10.79; Infant Bacterial Therapeutics AB is scheduled to report earnings on November 13, 2026, and the estimated EPS forecast is $-2.67. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 4.00K | $ 77.00K | $ 12.00K | $ 0.00 |
| Gross Profit | $ 0.00 | $ 4.00K | $ 77.00K | $ 12.00K | $ 0.00 |
| Operating Income | $ -61.95M | $ -139.90M | $ -134.62M | $ -65.81M | $ -44.58M |
| EBITDA | $ -68.18M | $ -136.09M | $ -122.25M | $ -64.34M | $ -43.76M |
| Net Income | $ -65.17M | $ -136.91M | $ -123.07M | $ -65.45M | $ -44.99M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 144.01M | $ 223.39M | $ 329.06M | $ 335.84M | $ 386.75M |
| Total Assets | $ 161.75M | $ 239.57M | $ 351.33M | $ 349.62M | $ 408.48M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -144.01M | $ -223.39M | $ -329.06M | $ -335.84M | $ -386.75M |
| Total Liabilities | $ 56.42M | $ 69.30M | $ 46.18M | $ 17.91M | $ 13.22M |
| Stockholders' Equity | $ 105.33M | $ 170.26M | $ 305.15M | $ 331.71M | $ 395.25M |
| Cash Flow | |||||
| Free Cash Flow | $ -72.34M | $ -113.13M | $ -101.22M | $ -85.80M | $ -55.62M |
| Operating Cash Flow | $ -72.34M | $ -113.13M | $ -101.22M | $ -85.80M | $ -55.62M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ -4.15M | $ -1.00K | $ 0.00 |
| Financing Cash Flow | $ 0.00 | $ 2.01M | $ 96.52M | $ 1.88M | $ 91.00K |
Currency in SEK